Elan inks strategic deal with PPD to accelerate development

By Nick Taylor

- Last updated on GMT

Related tags Ppd Boehringer ingelheim

Elan has inked a strategic collaboration with PPD to support simultaneous advancement of multiple clinical development programmes.

The deal makes PPD the primary service provider for all development functions and activities at Elan. Working closely with PPD allows Elan to expand its global development capabilities and accelerate progress of multiple pipeline compounds.

"PPD will act as a strategic collaborator and deliver capabilities, resources and expertise that will enable us to advance our business on a global scale while capturing efficiencies and flexibility​", said Doug Love, head of alliance management at Elan.

Services covered by the deal include project and data management, biostatistics, clinical and medical monitoring, quality assurance and pharmacovigilance. Elan plans to build on this initial deal to leverage the companies’ respective capabilities as and when opportunities arise.

Internal capabilities

In January Elan laid-off 130 employees, around half of who worked at its San Francisco R&D site, but emphasised its commitment to in-house talent in the PPD release. PPD is providing a range of services but this is to complement, rather than replace, internal capabilities, says Elan.

The ability to fluidly access additional expertise and execution capability on a global scale will complement our internal talent and may enable us to move multiple programs forward in a parallel manner​”, said Eliseo Salinas, head of development at Elan.

Clinical pipeline products at Elan include treatments for Alzheimer’s and autoimmune diseases. Elan will continue to invest in the​“world-leading work in biology​” that developed these products, said David Grange, CEO of PPD, while benefiting from the scale offered by its service provider.

Outsourcing deals

The PPD partnership comes two weeks after Elan outsourced antibody technical development, clinical manufacture and related regulatory filing support to Boehringer Ingelheim.

Johannes Roebers, head of biologic strategy, planning and operations at Elan, said: “The agreement enables Elan to focus resources on discovery and the clinical progression of our science while leveraging Boehringer Ingelheim’s process development and production capabilities​.”

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more